Latest:
IP Attorneys Propose a New Biosimilar Pathway in Case of ACA Repeal
© 2025 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Authors
Camlyn Masuda, PharmD, BCACP, CDCES
Camlyn Masuda, PharmD, BCACP, CDCES, is an associate specialist of pharmacy practice at the Daniel K. Inouye College of Pharmacy at the University of Hawai’i at Hilo.
Latest:
Common Patient Questions About Insulin Biosimilars Pertain to Classification
Nuances in classification for insulin biosimilars can lead to frequent areas of confusion, according to 2 pharmacists.
Ted Mathias, JD
Ted Mathias focuses on trying patent cases. In the last 2 years, he tried 2 cases to judgment and served as lead counsel in a case involving 33 patents that settled favorably on the eve of trial. Mathias has litigated patent cases and handled successful appeals to the Federal Circuit in the areas of medical devices, pharmaceuticals, mechanical devices, e-commerce and software.
Latest:
Opinion: Purple Book Patent Listings Are Only a First Step
Intellectual property attorneys from Axinn discuss the limitations of the Purple Book patent disclosure requirements and the burden these impose on biosimilar developers.
Mayuri Mathuria, MBA
Mayuri Mathuria, MBA, is a consultant in
Latest:
The Next Frontier: Oncology Biosimilars in 2025 and Beyond
The US oncology biosimilar market has rapidly evolved since its launch in 2017, driven by steep price discounts, payer adoption, and provider confidence, with an upcoming wave of biosimilars targeting blockbuster biologics promising further market growth, cost savings, and broader patient access.
Brooke McCormick
Brooke McCormick is an assistant editor for
Latest:
Dr Prerakkumar Parikh Reacts to FDA Approvals for First Neurology, Tocilizumab Biosimilars
Prerakkumar Parikh, PharmD, director of specialty clinical solutions at Magellan Rx Management, reacts to recent FDA approvals for the first natalizumab and tocilizumab biosimilars.
Advertisement
Advertisement